VIA
ACHN

Vident Investment Advisory’s Achillion Pharmaceuticals ACHN Stock Holding History

Vident Investment Advisory’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-84,625
Closed -$350K – 509
2016
Q4 		$350K Buy
+84,625
New +$450K 0.04% 355
2016
Q2 		– Sell
-272,122
Closed -$2.1K – 399
2016
Q1 		$2.1K Buy
272,122
+141,437
+108% +$1.04M 0.13% 294
2015
Q4 		$1.41M Buy
+130,685
New +$1.19M 0.18% 259
2015
Q3 		– Sell
-193,930
Closed -$1.72M – 1184
2015
Q2 		$1.72M Buy
+193,930
New +$1.83M 0.23% 117

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vident Investment Advisory's ACHN Position: Q1 2017 in Review

Vident Investment Advisory sold out of Achillion Pharmaceuticals (ACHN) in Q1 2017, closing a stake of 84,625 shares — an estimated $350K sold.

Vident Investment Advisory first reported a position in ACHN in Q2 2015 and held it in 4 quarters. The position peaked at $1.72M in Q2 2015. 130 funds tracked by Wall St. Rank hold ACHN as of Q1 2017.

  • Vident Investment Advisory reported no remaining Achillion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Vident Investment Advisory sold 84,625 Achillion Pharmaceuticals shares in Q1 2017, an estimated $350K.
  • Vident Investment Advisory first reported a position in Achillion Pharmaceuticals in Q2 2015 and held it in 4 quarters.
  • Vident Investment Advisory's Achillion Pharmaceuticals position peaked at $1.72M in Q2 2015.
  • 130 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2017.

Based on Vident Investment Advisory's 13F filing for Q1 2017, filed 10 May 2017.